Ichnos Glenmark Innovation announced ISB 2301, a first-in-class multispecific antibody targeting solid tumors by activating T and NK cells.
The candidate targets three tumor-associated antigens and is engineered using IGI's proprietary BEAT® technology platform.
IGI plans to submit an Investigational New Drug (IND) application for ISB 2301 by the end of 2026.
The development follows IGI's prior success with ISB 2001, which attracted a collaboration with AbbVie.